After becoming the first Spanish laboratory to obtain full certification in accordance with Regulation (EU) 2017/745 (MDR) for cross-linked hyaluronic acid dermal fillers with mesofiller® nexha, mesoestetic® Pharma Group takes another step in its pharmaceutical evolution with the marketing of a botulinum toxin. This milestone represents a significant advance within its strategy of growth and innovation in the field of aesthetic medicine.
To achieve this, the company has signed an **agreement with PROTOX**, a leading company in **Korea**, a country recognized for its leadership in innovation, biotechnology, and excellence in the development of botulinum toxins. This agreement will allow mesoestetic® to become **the first pharmaceutical laboratory with Spanish capital to have permits to market a botulinum toxin** in the **European Union, the United Kingdom, and Switzerland**, consolidating its position as a relevant player in the sector and reaffirming its commitment to innovation and scientific excellence
“Our commitment to innovation has a clear objective: to offer medical and aesthetic professionals the most complete, safe, and advanced therapeutic arsenal, thereby driving our growth and leveraging the full potential of a rapidly expanding market. Our commitment focuses on the internal development of our own solutions, enhancing our scientific and technological capabilities, and resorting to strategic alliances with international companies only when they bring differential and complementary value to our vision of quality, rigor, and innovation,” declares Carles Font, Co-CEO & Chief Business Development Officer of mesoestetic® Pharma Group.
Félix Rovira, technical director, indicates that “botulinum toxin is a highly complex biological drug, requiring a high level of scientific knowledge, regulatory control, and commitment to quality. Therefore, we have carefully selected PROTOX as a strategic partner, a top-tier company with a solid track record in innovation and high-precision production processes. This collaboration guarantees the highest standards of innovation and safety and represents a significant advance in our ability to offer therapeutic solutions of the highest demand,” he highlights.
This milestone is part of the company's global strategy focused on innovation, clinical research, and therapeutic excellence, allocating more than 40% of annual profits to R&D projects.
mesoestetic® Pharma Group's leadership in innovation and regulation has recently materialized with the launch of mesofiller® nexha, a hyaluronic acid line that combines correction and biostimulation in a single treatment, and with the achievement of MDR certification, one of the most demanding internationally. This recognition guarantees that the company's products, processes, and management systems meet the highest European standards of quality, safety, and efficacy, placing mesoestetic® at the forefront of the international medical-aesthetic sector
This new achievement takes place at a particularly significant moment for the group, which in 2025 commemorates forty years of innovation, research, and excellence in the service of aesthetic medicine.